dc.contributor.author | Akgun, Yeliz | |
dc.contributor.author | Bakirdogen, Serkan | |
dc.contributor.author | Kocak, Meral Gulay Kadioglu | |
dc.contributor.author | Bektas, Sibel | |
dc.contributor.author | Demir, Ceren | |
dc.contributor.author | Akbal, Erdem | |
dc.contributor.author | Elmas, Sait | |
dc.date.accessioned | 2020-12-02T18:01:44Z | |
dc.date.available | 2020-12-02T18:01:44Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0353-9504 | |
dc.identifier.issn | 1332-8166 | |
dc.identifier.uri | https://doi.org/10.3325/cmj.2019.60.431 | |
dc.identifier.uri | http://hdl.handle.net/11446/3711 | |
dc.description | WOS: 000506357400006 | en_US |
dc.description | PubMed: 31686457 | en_US |
dc.description.abstract | Aim To investigate the efficacy of adalimumab treatment in an experimental rat sclerosing encapsulated peritonitis (SEP) model. Methods the study involved 40 Wistar albino rats divided into four groups: chlorhexidine (CH) group, control group, CH + adalimumab group, and CH + resting group. the control group received normal saline intraperitoneally (i.p.). Other groups received 0.1% CH gluconate, 15% ethanol, and normal saline mixture i.p. for three weeks in order to induce SEP. CH + adalimumab group received 5 mg/kg adalimumab i.p. at the beginning of week 4 and week 6, while CH + resting group was followed-up for three weeks without applying any procedure after the onset of SEP. Rats in groups CH and control group were sacrificed on day 21, and rats in group CH + adalimumab and CH + resting were sacrificed on day 42. All groups were evaluated for peritoneal thickness, inflammation, vascularization, and fibrosis. Results CH + adalimumab group showed a significant decrease in peritoneal thickness, fibrosis score, and vascular score compared with CH group and CH + resting group. Conclusion Adalimumab can prevent SEP development. | en_US |
dc.description.sponsorship | Canakkale Onsekiz Mart University Scientific Research Projects UnitCanakkale Onsekiz Mart University [TTU-2016-840] | en_US |
dc.description.sponsorship | The study was supported by Canakkale Onsekiz Mart University Scientific Research Projects Unit (TTU-2016-840). | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Medicinska Naklada | en_US |
dc.identifier.doi | 10.3325/cmj.2019.60.431 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | Efficacy of adalimumab therapy in experimental rat sclerosing encapsulated peritonitis model | en_US |
dc.type | article | en_US |
dc.relation.journal | Croatian Medical Journal | en_US |
dc.department | DBÜ | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.volume | 60 | en_US |
dc.identifier.startpage | 431 | en_US |
dc.identifier.endpage | 438 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Akgun, Yeliz; Demir, Ceren] Canakkale Onsekiz Mart Univ, Sch Med, Dept Internal Med, Canakkale, Turkey; [Bakirdogen, Serkan] Canakkale Onsekiz Mart Univ, Sch Med, Dept Nephrol, Canakkale, Turkey; [Kocak, Meral Gulay Kadioglu] Okmeydani Educ & Res Hosp, Dept Nephrol, Minist Hlth, Istanbul, Turkey; [Bektas, Sibel] Hlth Sci Univ, Gaziosmanpasa Educ & Res Hosp, Sch Med, Dept Pathol, Istanbul, Turkey; [Akbal, Erdem] Bilim Univ, Sch Med, Dept Gastroenterol, Istanbul, Turkey; [Elmas, Sait] Canakkale Onsekiz Mart Univ Canakkale, Expt Med & Res Ctr, Canakkale, Turkey | en_US |